Reuters
—
(Reuters) - BioNtech SE, Europe's largest unlisted biotech firm by staff numbers, said on Tuesday that it planned to raise up to $303.6 million in an initial public offering in the United States. The company expects its offering of about 15.2 million American depositary shares, including underwriters' option, to be priced between $18 and $20, BioNtech said in a regulatory filing.